Clinical Trials

LB Pharmaceuticals initiates patient dosing in phase 1 study of LB-102 for treatment of schizophrenia

LB Pharmaceuticals, Inc., (“LB”, or the “Company”) a biotechnology company focused on developing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1 clinical trial.

Roche’s risdiplam achieves primary endpoint in infant-related spinal muscular atrophy trial

Roche announced that its risdiplam has achieved primary endpoint in the FIREFISH study in infants with type 1 spinal muscular atrophy.

Verrica Pharmaceuticals announces presentation of positive data from new pooled analysis of phase 3 CAMP trials of VP-102

Verrica Pharmaceuticals announced the presentation of positive data from a post-hoc pooled analysis of the pivotal Phase 3 CAMP trials evaluating the safety and efficacy of VP-102 (cantharidin 0.7% topical solution), Verrica’s lead product candidate for the treatment of molluscum contagiosum (molluscum).

Innovation Pharmaceuticals announces dose escalation

Innovation Pharmaceuticals, a clinical stage pharmaceutical company, announced that the company has received agreement from the study’s Dose Escalation Committee (DEC) to progress dosing to the second cohort in its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers.

Neuroptika announces enrolment of first patient in phase 2 clinical trial for dry eye disease

Neuroptika, a privately held biotechnology company focused on the development of novel regenerative treatments for ophthalmic diseases, announced that the first patient was enrolled in a Phase 2 clinical trial of NRO-1 for the treatment of dry eye disease.

VBI Vaccines announces second pivotal phase 3 study of Sci-B-Vac meets primary and secondary endpoints

VBI Vaccines has reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac, the company’s trivalent hepatitis B (HBV) vaccine, and comparing safety and immunogenicity of Sci-B-Vac to GlaxoSmithKline’s currently-marketed HBV vaccine, Engerix-B.

Catabasis, Duchenne UK announce partnership to evaluate edasalonexent in phase 2 non-ambulatory DMD trial

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular dystrophy (DMD), have entered into a partnership for a Phase 2 trial of edasalonexent, a novel NF-kB inhibitor, in non-ambulatory DMD patients.

Veristat strengthens its European presence with acquisition of The Clinical Trial Company

Veristat, a full-service CRO, announced that it has completed the acquisition of The Clinical Trial Company, a global Contract Research Organization headquartered in Europe.

Exelixis enters into a clinical collaboration for three phase 3 combination trials in advanced solid tumours

Exelixis announced a collaboration agreement with Roche to evaluate cabozantinib (CABOMETYX), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, in combination with atezolizumab (TECENTRIQ), Roche’s PD-L1 immune checkpoint inhibitor, in patients with locally advanced or metastatic solid tumours.